Interdisziplinäre Tumorkonferenz – Progredientes invasiv-duktales Mammakarzinom unter neoadjuvanter Chemotherapie in der Schwangerschaft

Der folgende Beitrag stellt eine 30jährige Patientin, IIG IP in der 31. Schwangerschaftswoche, mit extern histologisch gesichertem Mammakarzinom vor.

• Literatur

• 1 Kaufmann M, Hortobagyi GN, Goldhirsch A et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24: 1940-9
• 2 Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania. Cancer 2004; 100: 2512-32
• 3 Huober J, von Minckwitz G, Denkert C et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast cancer research and treatment 2010; 124: 133-40
• 4 Untch M, von Minckwitz G. Neoadjuvant chemotherapy: early response as a guide for further treatment: clinical, radiological, and biological. Journal of the National Cancer Institute Monographs 2011; 2011: 138-41
• 5 Empfehlungen der Arbeitsgemeinschaft für Gynäkologische Onkologie, Kommission Mamma. Deutsche Version 2012. 1D (Stand: März 2012)
• 6 Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of the National Cancer Institute Monographs 2001; 96-102
• 7 Caudle AS, Gonzalez-Angulo AM, Hunt KK et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. Journal of clinical oncology 2010; 28: 1821-8
• 8 Kaufmann M, von Minckwitz G, Mamounas EP et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Annals of surgical oncology 2012; 19: 1508-16